Synthesis, binding affinity, and relaxivity of target-specific MRI contrast agents

Journal of Inclusion Phenomena and Macrocyclic Chemistry

Volumn 59, Issue 3-4, 2007, Pages 323-329

  Zigelboim, Isaac ^a   Offen, Daniel ^a   Melamed, Eldad ^a   Panet, Hana ^a   Rehavi, Moshe ^a   Cohen, Yoram ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Dopamine receptor; Gadolinium complexes; MR molecular imaging; MRI contrast agents; Targeted contrast agents

Indexed keywords

EID: 36048962437     PISSN: 09230750     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10847-007-9331-2     Document Type: Article

References (29)

1. Stark, D.D., Bradley, W.G., Jr. (Eds.): Magnetic Resonance Imaging. Vol. 1-3, (3rd edn.), Mosby, Saint-Louis, USA (1991)
2. (a) Lauffer, R.B.: Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design. Chem. Rev. 87, 901-927 (1987).
3. (b) Caravan, P., Ellison, J.J., McMurry, T.J., Lauffer, R.B.: Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem. Rev. 99, 2293-2352 (1999).
4. (c) Merbach, A.E., Toth, E.: The chemistry of contrast agents in medical magnetic resonance imaging. John Wiley & Sons, Chichester (2001)
5. (a) Jacques, V., Desreux, J.F.: New classes of MRI contrast agents. Top. Curr. Chem. 221, 123-164 (2002).
6. (b) Lanza, G.M., Winter, P., Caruthers, S., Schmeider, A., Crowder, K., Morawski, A., Zhang, HY., Scott, M.J., Wickline, S.A.: Targeting steroid hormone receptor pathways in the treatment of hormone dependent cancers. Curr. Pharm. Biotechnol. 5, 495-507 (2004)
7. (a) Weissleder, R., Mahmood, U.: Molecular imaging. Radiology 219, 316-333 (2001).
8. (b) Graves, E.E., Weissleder, R., Ntziachristos, V.: Fluorescence molecular imaging of small animal tumor models. Curr. Mol. Med. 4, 419-430 (2004).
9. (c) Gross, S., Piwnica-Worms, D.: Spying on cancer: molecular imaging in vivo with genetically encoded reporters. Cancer Cell 7, 5-15 (2005).
10. (d) Doubrovin, M., Serganova, I., Mayer-Kuckuk, P., Ponomarev, V., Blasberg, R.G.: Multimodality in vivo molecular-genetic imaging. Bioconjug. Chem. 15, 1376-1388 (2004)
11. (a) Contag, P.R.: Whole-animal cellular and molecular imaging to accelerate drug development. Drug Discov. Today 7, 555-562 (2002).
12. (b) Gambhir S.S.: Molecular imaging of cancer with positron emission tomography. Nat. Rev. Cancer 2, 683-693 (2002).
13. (c) Weissleder, R.: Scaling down imaging: molecular mapping of cancer in mice. Nat. Rev. Cancer 2, 11-18 (2002).
14. (d) Rudin, M., Weissleder, R.: Molecular imaging in drug discovery and development. Nat. Rev. Drug Discov. 2, 123-131 (2003).
15. (e) Phelps, M.E.: Molecular imaging with positron emission tomography. Annu. Rev. Nucl. Part. Sci. 52, 303-338 (2002)
16. (a) Moats, R.A., Fraser, S.E., Meade, T.J.: A "Smart" magnetic resonance imaging agent that reports on specific enzymatic activity. Angew. Chem. Int. Ed. Engl. 36, 726-728 (1997).
17. (b) Louie, A.Y., Huber, M.M., Ahrens, E.T., Rothbacher, U., Moas, R., Jacobs, R.e., Fraser, S.E., Meade, T.J.: In vivo visualization of gene expression using magnetic resonance imaging. Nat. Biotechnol. 18, 321-325 (2000).
18. (c) Weissleder, R., Moore, A., Mahmood, U., Bhorade, R., Benveniste, H., Chiocca, E.A., Basilion, J.P.: In vivo magnetic resonance imaging of transgene expression. Nat. Med. 6, 351-355 (2000).
19. (d) Högemann, D., Basilion, J.P.: "Seeing inside the body": MR imaging of gene expression. Eur. J. Nucl. Med. 29, 400-408 (2002).
20. (e) Genove, G., DeMarco, U., Xu, H., Goins, W., Ahrens, E.T.: A new transgene reporter for in vivo magnetic resonance imaging. Nat. Med. 11, 450-454 (2005)
21. (a) McGeer, P.L., Eccles, J.C., McGeer, E.G.: Molecular neurobiology of the mammalian brain, (2nd edn.), pp.284-308. Plenum Press, New York (1987) Chapter 9.
22. (b) Blum, D., Torch, S., Lambeng, N., Nissou, M.F., Benabid, A.L., Sadoul, R., Verna, J.M.: Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65, 135-172 (2001).
23. (c) Davis, K.L., Kahn, R.S., Ko, G., Davidson, M.: Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 148, 1474-1486 (1991)
24. (a) Bunnett, J.P., Wooten, G.F.: Dopamine denervation does not alter in vivo 3H-spiperone binding in rat striatum: implications for external imaging of dopamine receptors in Parkinson's disease. Ann. Neurol. 19, 378-383 (1986).
25. (b) Hansen, H.C., Olsson, R., Croston, G., Andersson, C.M.: Multistep solution-Phase parallel synthesis of spiperone analogues. Bioorg. Med. Chem. Lett. 10, 2435-2439 (2000)
26. Dischino, D.D., Delaney, E.J., Emswiler, J.E., Gaughan, G.T., Prasad, J.S., Sirvastava, S.K., Tweedle, M.F.: Synthesis of nonionic gadolinium chelates useful as contrast agents for magnetic resonance imaging: 1,4,7- tris(carboxymethyl)-10-substituted-1,4,7,10-tetraazacyclododecanes and their corresponding gadolinium chelates. Inorg. Chem. 30, 1265-1269 (1991)
27. Gordon, I., Weizman, R., Rehavi, M.: Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. Eur. J. Pharmacol. 298, 27-30 (1996)
28. (a) Kalani, M.Y.S., Vaidehi, N., Hall, S.E., Trabanino, R.J., Freddolino, P.L., Kalani, M.A., Floriano, W.B., Kam, V.W.T., Goddard, W.A. III.: The predicted 3D structure of the human D2 dopamine receptor and the binding site and binding affinities for agonists and antagonists. Proc. Natl. Acad. Sci. U.S.A. 101, 3815-3820 (2004).
29. (b) Hansen, C.H., Olsson, R., Croston, G., Andersson, C.M.: Multistep solution-Phase parallel synthesis of spiperone analogues. Bioorg. Med. Chem. Lett. 10, 2435-2439 (2000)